人才队伍

        著名外科学专家，教授，主任医生，博士生导师，浙江大学医学院副院长，浙江大学医学院附属邵逸夫医院院长。兼任中华医学会外科学分会副主任委员、中国医生协会外科医生分会微创外科医生委员会主任委员、国务院学位委员会临床医学学科评议组成员、浙江省医学会外科学分会主任委员、浙江大学微创外科研究所所长、浙江省腔镜技术研究重点实验室主任、科技部重点领域创新团队——腔镜技术创新团队负责人、美国外科学院Fellow、英国皇家外科学院Fellow、香港大学荣誉教授。入选“新世纪百千万人才工程”国家级人选、“长江学者”特聘教授、卫生部有突出贡献中青年专家、国家“万人计划”科技创新领军人才、浙江省首批“特级专家”、浙江省151人才工程第一层次，享受国务院特殊津贴。

研究与成果：从事临床工作三十余年，在肝胆胰外科方面取得了令人瞩目的成就：成功完成1000余例腹腔镜下肝脏切除手术，是国际腹腔镜肝脏外科的权威专家；在国际上完成首例完全腹腔镜下绕肝带法二步肝切除术，该术式被认为是肝脏外科治疗领域最有前景的创新之举；开发了腹腔镜刮吸法断肝技术、腹腔镜下区域性肝血流阻断技术、腹腔镜二级脾蒂离断法脾脏切除技术等腹腔镜新技术，显著提高了腹腔镜技术的安全性，创建了国内首个微创医学学科，主持开展了腹腔镜肝脏切除手术培训课程，并成为国内唯一通过英格兰皇家外科学院认证的肝脏课程。大量创造性的工作对我国腹腔镜技术的普及和微创医学的发展起到了极大的推动作用。

荣获国家技术发明二等奖1项、国家科技进步二等奖2项、教育部科技进步一等奖1项、浙江省科技进步一等奖3项、梁何利科学与技术创新奖、浙江省科学技术奖重大贡献奖、吴阶平医药创新奖等。他建立了腹腔镜刮吸解剖法肝切除术、腹腔镜下区域性肝血流阻断技术，在国际上完成首例完全腹腔镜下绕肝带法二步肝切除术，创建了国内首个微创医学学科。

代表性论文：

[1] Pan L, Chen M, Ji L, Zheng L, Yan P, Fang J, Zhang B, Cai X. The Safety and Efficacy of Laparoscopic Common Bile Duct Exploration Combined with Cholecystectomy for the Management of Cholecysto-choledocholithiasis: An Up-to-date Meta-analysis. Ann Surg. 2018 Aug;268(2):247-253.

[2]Xie C, Cen D, Ren Z, Wang Y, Wu Y, Li X, Han G, Cai X. FeS@BSA Nanoclusters to Enable H₂S-Amplified ROS-Based Therapy with MRI Guidance. Adv Sci (Weinh). 2020 Feb 19;7(7):1903512.

[3] Li S, Topatana W, Juengpanich S, Cao J, Hu J, Zhang B, Ma D, Cai X, Chen M. Development of synthetic lethality in cancer: molecular and cellular classification. Signal Transduct Target Ther. 2020 Oct 19;5(1):241. doi: 10.1038/s41392-020-00358-6. PMID: 33077733; PMCID: PMC7573576.

[4] Chen M, Zhang B, Topatana W, Cao J, Zhu H, Juengpanich S, Mao Q, Yu H, Cai X. Classification and mutation prediction based on histopathology H&E images in liver cancer using deep learning. NPJ Precis Oncol. 2020 Jun 8;4:14. doi: 10.1038/s41698-020-0120-3.

[5] Topatana W, Juengpanich S, Li S, Cao J, Hu J, Lee J, Suliyanto K, Ma D, Zhang B, Chen M, Cai X. Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation. J Hematol Oncol. 2020 Sep 3;13(1):118.

[6] Lin Z, Xia S, Liang Y, Ji L, Pan Y, Jiang S, Wan Z, Tao L, Chen J, Lin C, Liang X, Xu J, Cai X. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription. Theranostics. 2020 Jul 11;10(19):8834-8850.

[7] Hou L, Zhao J, Gao S, Ji T, Song T, Li Y, Wang J, Geng C, Long M, Chen J, Lin H, Cai X, Cang Y. Restriction of hepatitis B virus replication by c-Abl-induced proteasomal degradation of the viral polymerase. Sci Adv. 2019 Feb 6;5(2):eaau7130.

[8] Guo T, Feng YL, Xiao JJ, Liu Q, Sun XN, Xiang JF, Kong N, Liu SC, Chen GQ, Wang Y, Dong MM, Cai Z, Lin H, Cai XJ, Xie AY. Harnessing accurate non-homologous end joining for efficient precise deletion in CRISPR/Cas9-mediated genome editing. Genome Biol. 2018 Oct 19;19(1):170. 

[9] Feng YL, Xiang JF, Liu SC, Guo T, Yan GF, Feng Y, Kong N, Li HD, Huang Y, Lin H, Cai XJ, Xie AY. H2AX facilitates classical non-homologous end joining at the expense of limited nucleotide loss at repair junctions. Nucleic Acids Res. 2017 Oct 13;45(18):10614-10633. 

[10] Wu D, Xue D, Zhou J, Wang Y, Feng Z, Xu J, Lin H, Qian J, Cai X. Extrahepatic cholangiography in near-infrared II window with the clinically approved fluorescence agent indocyanine green: a promising imaging technology for intraoperative diagnosis. Theranostics. 2020 Feb 19;10(8):3636-3651.

[11] Li G, Ji T, Chen J, Fu Y, Hou L, Feng Y, Zhang T, Song T, Zhao J, Endo Y, Lin H, Cai X, Cang Y. CRL4^DCAF8 Ubiquitin Ligase Targets Histone H3K79 and Promotes H3K9 Methylation in the Liver. Cell Rep. 2017 Feb 7;18(6):1499-1511.

[12] Wei S, Tang J, Cai X. Founder cells for hepatocytes during liver regeneration: from identification to application. Cell Mol Life Sci. 2020 Aug;77(15):2887-2898.

[13] Ying H, Ji L, Xu Z, Fan X, Tong Y, Liu H, Zhao J, Cai X. TRIM59 promotes tumor growth in hepatocellular carcinoma and regulates the cell cycle by degradation of protein phosphatase 1B. Cancer Lett. 2020 Mar 31;473:13-24. 

[14] Zhai S, Lin S, Lin Z, Xu J, Ji T, Chen K, Wu K, Liu H, Ying H, Fei W, Wang J, Fu G, Wang Y, Hu X, Cai X. eIF4EBP3 was downregulated by methylation and acted as a tumor suppressor by targeting eIF4E/β-catenin in gastric cancer. Gastric Cancer. 2020 May;23(3):483-496.

[15] Liu X, Hu X, Kuang Y, Yan P, Li L, Li C, Tao Q, Cai X. BCLB, methylated in hepatocellular carcinoma, is a starvation stress sensor that induces apoptosis and autophagy through the AMPK-mTOR signaling cascade. Cancer Lett. 2017 Jun 1;395:63-71. 

[16] Shi L, Lin H, Li G, Sun Y, Shen J, Xu J, Lin C, Yeh S, Cai X, Chang C. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals. Cancer Lett. 2016 Apr 1;373(1):45-56.

[17]  Chen J, Jin R, Zhao J, Liu J, Ying H, Yan H, Zhou S, Liang Y, Huang D, Liang X, Yu H, Lin H, Cai X. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Lett. 2015 Oct 10;367(1):1-11. 

[18] Xu J, Zheng L, Chen J, Sun Y, Lin H, Jin RA, Tang M, Liang X, Cai X. Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals. Cell Death Dis. 2017 Oct 12;8(10):e3095. doi: 10.1038/cddis.2017.411. PMID: 29022906; PMCID: PMC5680567.

[19] Xia S, Pan Y, Liang Y, Xu J, Cai X. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine. 2020 Jan;51:102610.

[20] Xu J, Lin H, Li G, Sun Y, Chen J, Shi L, Cai X, Chang C. The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals. EBioMedicine. 2016 Oct;12:55-67.

[21]Xu J, Lin H, Li G, Sun Y, Shi L, Ma WL, Chen J, Cai X, Chang C. Sorafenib with ASC-J9^® synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals. Int J Cancer. 2017 Feb 1;140(3):705-717.

[22]Shi L, Lin H, Li G, Jin RA, Xu J, Sun Y, Ma WL, Yeh S, Cai X, Chang C. Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression. Mol Cancer Ther. 2016 Apr;15(4):731-742.

招生信息：微创医学、外科学(科学及专业）硕士、博士